{"id":"W4416019222","doi":"10.1016/j.ijgc.2025.102160","title":"POST-(NEO)ADJUVANT THERAPY OUTCOMES WITH LENVATINIB PLUS PEMBROLIZUMAB IN PARTICIPANTS WITH ADVANCED OR RECURRENT ENDOMETRIAL CANCER: RESULTS FROM STUDY 309/KEYNOTE-775 AND ENGOT-EN9/LEAP-001","year":2025,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Pembrolizumab; Lenvatinib; MEDLINE; Compassionate Use; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001309244,0.0003407977,0.0006705751,0.0001867331,0.000280707,0.0005394816,0.0004768969,0.0006583658,0.002291628],"category_scores_gemma":[0.003073167,0.0002086066,0.002383474,0.000400881,0.0001768257,0.0006943468,0.0005307877,0.00126855,0.0002943189],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004611689,"about_ca_system_score_gemma":0.0008078988,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004706467,"about_ca_topic_score_gemma":0.008070443,"domain_scores_codex":[0.9993191,0.0002285525,0.00007764111,0.0001543086,0.00006767367,0.0001527366],"domain_scores_gemma":[0.9988136,0.0002606765,0.0004467368,0.00008456601,0.0001324112,0.0002619994],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1516801,0.003515329,0.7699149,0.001759669,0.01237238,0.0001762146,0.0003803399,0.0003733288,0.001797127,0.0002012679,0.003460528,0.05436888],"study_design_scores_gemma":[0.007041603,0.01455208,0.9645264,0.0002924691,0.00973247,0.0001038282,0.0003723138,0.000298457,0.0004813148,0.0002388523,0.00232636,0.00003378155],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9923074,0.004210456,0.00009534074,0.0002917994,0.00009705182,0.00007736022,0.00211019,0.000006403442,0.0008040122],"genre_scores_gemma":[0.9957945,0.001107765,0.0001156268,0.0002670825,0.00007498007,0.0001406486,0.001697999,0.000003747141,0.0007976333],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004706467,"threshold_uncertainty_score":0.009358168,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09727618982288361,"score_gpt":0.4481342611936658,"score_spread":0.3508580713707822,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}